Osteoporosis International

, Volume 21, Issue 5, pp 723–732

Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity

  • P. Musette
  • M. L. Brandi
  • P. Cacoub
  • J. M. Kaufman
  • R. Rizzoli
  • J.-Y. Reginster
Review

Abstract

Summary

Cutaneous adverse reactions are reported for many treatments including antiosteoporotic agents. This position paper includes an algorithm for their recognition. With early recognition and proper management, including immediate and permanent withdrawal of the culprit agent, accompanied by hospitalization, rehydration, and systemic corticosteroids, if necessary, the prognosis is good.

Introduction

Cutaneous adverse reactions are reported for many therapeutic agents and observed in between 0% and 8% of treated patients depending on the drug. The antiosteoporotic agents are reputed to be safe in terms of cutaneous effects; however, there have been a number of case reports of cutaneous adverse reactions, which merit consideration. This was the subject of a Working Group meeting of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis in April 2009, to focus on the impact of cutaneous adverse reactions and drug-induced hypersensitivity in the management of postmenopausal osteoporosis. We prepared this position paper following these discussions, and include an algorithm for their recognition.

Methods

We reviewed cutaneous adverse reactions observed with antiosteoporotic agents, including information from case reports, regulatory documents, and pharmacovigilance.

Results

The cutaneous adverse reactions range from benign reactions including exanthematous or maculopapular eruption (drug rash), photosensitivity, and urticaria to the severe and potentially life-threatening reactions, angioedema, drug rash with eosinophilia and systemic symptoms (DRESS), Stevens Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). Review of available evidence shows that cutaneous adverse reactions occur with all commonly used antiosteoporotic agents. Notably, there are reports of SJS and TEN for bisphosphonates, and of DRESS and TEN for strontium ranelate. These severe reactions remain very rare (<1 in 10,000 cases).

Conclusion

With early recognition and proper management, including immediate and permanent withdrawal of the culprit agent, accompanied by hospitalization and rehydration and systemic corticosteroids if necessary, the prognosis is good.

Keywords

Anti-osteoporotic treatments Cutaneous adverse reactions Hypersensitivity reactions Osteoporosis 

References

  1. 1.
    Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255–59CrossRefPubMedGoogle Scholar
  2. 2.
    Hunziker T, Kunzi UP, Braunschweig S, Zehnder D, Hoigne R (1997) Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy 52:388–93CrossRefPubMedGoogle Scholar
  3. 3.
    Bigby M (2001) Rates of cutaneous reactions to drugs. Arch Dermatol 137:765–70PubMedGoogle Scholar
  4. 4.
    US Food and Drugs Administration (2009) PharmapendiumGoogle Scholar
  5. 5.
    Gomes ER, Demoly P (2005) Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 5:309–16CrossRefPubMedGoogle Scholar
  6. 6.
    Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT (2005) HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 102:4134–39CrossRefPubMedGoogle Scholar
  7. 7.
    Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT (2004) Medical genetics: a marker for Stevens Johnson syndrome. Nature 428:486CrossRefPubMedGoogle Scholar
  8. 8.
    Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jagel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A (2008) HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 358:568–79CrossRefPubMedGoogle Scholar
  9. 9.
    Mockenhaupt M (2007) Epidemiology and causes of severe cutaneous adverse reactions to drugs, pp 18–31Google Scholar
  10. 10.
    Eshki M, Allanore L, Musette P, Milpied B, Grange A, Guillaume JC, Chosidow O, Guillot I, Paradis V, Joly P, Crickx B, Ranger-Rogez S, Descamps V (2009) Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol 145:67–72CrossRefPubMedGoogle Scholar
  11. 11.
    Roujeau JC (2005) Clinical heterogeneity of drug hypersensitivity. Toxicology 209:123–29CrossRefPubMedGoogle Scholar
  12. 12.
    Svensson CK, Cowen EW, Gaspari AA (2001) Cutaneous drug reactions. Pharmacol Rev 53:357–79PubMedGoogle Scholar
  13. 13.
    Aberer W, Kranke B (2008) Clinical manifestations and mechanisms of skin reactions after systemic drug administration. Drug Discovery Today 5:e237–e247CrossRefGoogle Scholar
  14. 14.
    Valeyrie-Allanore L, Sassolas B, Roujeau JC (2007) Drug-induced skin, nail and hair disorders. Drug Saf 30:1011–30CrossRefPubMedGoogle Scholar
  15. 15.
    Morison WL (2004) Clinical practice. Photosensitivity. N Engl J Med 350:1111–17CrossRefPubMedGoogle Scholar
  16. 16.
    Wolf R, Orion E, Marcos B, Matz H (2005) Life-threatening acute adverse cutaneous drug reactions. Clin Dermatol 23:171–81CrossRefPubMedGoogle Scholar
  17. 17.
    Bocquet H, Bagot M, Roujeau JC (1996) Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS). Semin Cutan Med Surg 15:250–257CrossRefPubMedGoogle Scholar
  18. 18.
    Shiohara T, Takahashi R, Kano Y (2007) Drug-induced hypersensitivity syndrome and viral reactivation, pp. 251-266Google Scholar
  19. 19.
    Borchers AT, Lee JL, Naguwa SM, Cheema GS, Gershwin ME (2008) Stevens-Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev 7:598–605CrossRefPubMedGoogle Scholar
  20. 20.
    Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A (2008) Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 128:35–44CrossRefPubMedGoogle Scholar
  21. 21.
    Ghislain PD, Roujeau JC (2002) Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 8:5PubMedGoogle Scholar
  22. 22.
    Allanore L, Roujeau JC (2007) Clinic and pathogenesis of severe bullous skin reactions: Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, pp. 267–277Google Scholar
  23. 23.
    Shiohara T, Inaoka M, Kano Y (2006) Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int 55:1–8CrossRefPubMedGoogle Scholar
  24. 24.
    Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE (1998) Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282:490–493CrossRefPubMedGoogle Scholar
  25. 25.
    Faye O, Roujeau JC (2005) Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date. Drugs 65:2085–90CrossRefPubMedGoogle Scholar
  26. 26.
    European Medicines Agency (2008) Alendronate. Summary of product characteristicsGoogle Scholar
  27. 27.
    Kimura M, Kawada A, Murayama Y, Murayama M (2003) Drug eruption due to alendronate sodium hydrate. Contact Dermatitis 48:116CrossRefPubMedGoogle Scholar
  28. 28.
    Kontoleon P, Ilias I, Stavropoulos PG, Papapetrou PD (2000) Urticaria after administration of alendronate. Acta Derm Venereol 80:398PubMedGoogle Scholar
  29. 29.
    Biswas PN, Wilton LV, Shakir SA (2003) Pharmacovigilance study of alendronate in England. Osteoporos Int 14:507–14CrossRefPubMedGoogle Scholar
  30. 30.
    High WA, Cohen JB, Wetherington W, Cockerell CJ (2003) Superficial gyrate erythema as a cutaneous reaction to alendronate for osteoporosis. J Am Acad Dermatol 48:945–46CrossRefPubMedGoogle Scholar
  31. 31.
    Brinkmeier T, Kugler K, Lepoittevin JP, Frosch PJ (2007) Adverse cutaneous drug reaction to alendronate. Contact Dermatitis 57:123–25CrossRefPubMedGoogle Scholar
  32. 32.
    Lazarov A, Moss K, Plosk N, Cordoba M, Baitelman L (2002) Alendronate-induced lichen planus. Isr Med Assoc J 4:389–90PubMedGoogle Scholar
  33. 33.
    US Food and Drugs Administration (2002) Risedronate. DescriptionGoogle Scholar
  34. 34.
    (2009) Vidal 2009. Le Dictionnaire, 85th edGoogle Scholar
  35. 35.
    Barrera BA, Wilton L, Harris S, Shakir SA (2005) Prescription-event monitoring study on 13, 164 patients prescribed risedronate in primary care in England. Osteoporos Int 16:1989–98CrossRefPubMedGoogle Scholar
  36. 36.
    Belhadjali H, Slim R, Aouam K, Youssef M, Zili J (2008) Cutaneous vasculitis induced by risedronate. Allergy 63:1405CrossRefPubMedGoogle Scholar
  37. 37.
    European Medicines Agency (2007) Ibandronate. Summary of product characteristicsGoogle Scholar
  38. 38.
    European Medicines Agency (2008) Zoledronic acid. Summary of product characteristicsGoogle Scholar
  39. 39.
    Rizos EC, Milionis HJ, Elisaf MS (2006) Fever with rash following zolendronic acid administration. Clin Exp Rheumatol 24:455PubMedGoogle Scholar
  40. 40.
    European Medicines Agency (2008) Strontium ranelate. Summary of product characteristicsGoogle Scholar
  41. 41.
    Groves C (2008) Interstitial granulomatous reaction to strontium ranelate. Arch Dermatol 144:268–69CrossRefPubMedGoogle Scholar
  42. 42.
    Boada A, Carrascosa J, Leal L, Ferrandiz C (2009) Generalized cutaneous drug eruption due to strontium ranelate. J Eur Acad Dermatol Venereol 0 (in press)Google Scholar
  43. 43.
    Pernicova I, Middleton ET, Aye M (2008) Rash, strontium ranelate and DRESS syndrome put into perspective. European Medicine Agency on the alert. Osteoporos Int 19:1811–12CrossRefPubMedGoogle Scholar
  44. 44.
    Jonville-Bera AP, Crickx B, Aaron L, Hartingh I, utret-Leca E (2009) Strontium ranelate-induced DRESS syndrome: first two case reports. Allergy Google Scholar
  45. 45.
    Lee HY, Lie D, Lim KS, Thirumoorthy T, Pang SM (2009) Strontium ranelate-induced toxic epidermal necrolysis in a patient with post-menopausal osteoporosis. Osteoporos Int 20:161–62CrossRefPubMedGoogle Scholar
  46. 46.
    Grosso A, Douglas I, Hingorani A, MacAllister R, Smeeth L (2008) Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions. Br J Clin Pharmacol 66:689–94PubMedGoogle Scholar
  47. 47.
    European Medicines Agency (2008) Raloxifene. Summary of product characteristicsGoogle Scholar
  48. 48.
    Layton D, Clarke A, Wilton LV, Shakir SA (2005) Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring study. Osteoporos Int 16:490–500CrossRefPubMedGoogle Scholar
  49. 49.
    European Medicines Agency (2008) Teriparatide. Summary of product characteristicsGoogle Scholar
  50. 50.
    European Medicines Agency (2007) Parathyroid hormone. Summary of product characteristicsGoogle Scholar
  51. 51.
    Burnett-Bowie SA (2008) Is twice-yearly denosumab beneficial in postmenopausal women with osteopenia but no history of fracture? Nat Clin Pract Endocrinol Metab 4:660–661CrossRefPubMedGoogle Scholar
  52. 52.
    McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821–31CrossRefPubMedGoogle Scholar
  53. 53.
    Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353:878–82CrossRefPubMedGoogle Scholar
  54. 54.
    Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513–21CrossRefPubMedGoogle Scholar
  55. 55.
    Schnyder B, Pichler WJ (2009) Mechanisms of drug-induced allergy. Mayo Clin Proc 84:268–72CrossRefPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2009

Authors and Affiliations

  • P. Musette
    • 1
  • M. L. Brandi
    • 2
  • P. Cacoub
    • 3
  • J. M. Kaufman
    • 4
  • R. Rizzoli
    • 5
  • J.-Y. Reginster
    • 6
  1. 1.Department of Dermatology and INSERM Unit 905Charles Nicolle University HospitalRouenFrance
  2. 2.Department of Internal MedicineUniversity of FlorenceFlorenceItaly
  3. 3.Department of Internal MedicineAH-HP, Hôpital Pitié Salpétrière, and Université Pierre et Marie CurieParisFrance
  4. 4.UZ Gent Department of Internal MedicineGhentBelgium
  5. 5.Geneva University HospitalsGenevaSwitzerland
  6. 6.Department of Public Health SciencesUniversity of LiègeLiègeBelgium

Personalised recommendations